212 related articles for article (PubMed ID: 1679950)
1. Relationships between medication treatments and neuropsychological test performance in schizophrenia.
Sweeney JA; Keilp JG; Haas GL; Hill J; Weiden PJ
Psychiatry Res; 1991 Jun; 37(3):297-308. PubMed ID: 1679950
[TBL] [Abstract][Full Text] [Related]
2. Effects of anticholinergic medication on memory in schizophrenia.
Strauss ME; Reynolds KS; Jayaram G; Tune LE
Schizophr Res; 1990; 3(2):127-9. PubMed ID: 1980611
[TBL] [Abstract][Full Text] [Related]
3. Neuroleptic effects on neuropsychological test performance in schizophrenia.
Verdoux H; Magnin E; Bourgeois M
Schizophr Res; 1995 Jan; 14(2):133-9. PubMed ID: 7710993
[TBL] [Abstract][Full Text] [Related]
4. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
5. Neuroleptic drug effects on cognitive function in schizophrenia.
Cleghorn JM; Kaplan RD; Szechtman B; Szechtman H; Brown GM
Schizophr Res; 1990; 3(3):211-9. PubMed ID: 1980613
[TBL] [Abstract][Full Text] [Related]
6. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.
Minzenberg MJ; Poole JH; Benton C; Vinogradov S
Am J Psychiatry; 2004 Jan; 161(1):116-24. PubMed ID: 14702259
[TBL] [Abstract][Full Text] [Related]
7. Cognitive neuropsychological functioning in New Zealand Māori diagnosed with schizophrenia.
Kake TR; Garrett N; Te Aonui M
Aust N Z J Psychiatry; 2016 Jun; 50(6):566-76. PubMed ID: 26494850
[TBL] [Abstract][Full Text] [Related]
8. Neuroleptic dose reduction in older psychotic patients.
Harris MJ; Heaton RK; Schalz A; Bailey A; Patterson TL
Schizophr Res; 1997 Oct; 27(2-3):241-8. PubMed ID: 9416653
[TBL] [Abstract][Full Text] [Related]
9. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.
Poyurovsky M; Faragian S; Fuchs C; Pashinian A
Isr J Psychiatry Relat Sci; 2009; 46(3):213-20. PubMed ID: 20039523
[TBL] [Abstract][Full Text] [Related]
10. Influence of haloperidol on the relationship of frontal lobe function to psychomotor poverty and disorganization syndromes.
Allen DN; Anastasiou A; Goldstein G; Gilbertson M; van Kammen DP
Psychiatry Res; 2000 Feb; 93(1):33-9. PubMed ID: 10699226
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: one-year followup study.
Sweeney JA; Haas GL; Keilp JG; Long M
Psychiatry Res; 1991 Jul; 38(1):63-76. PubMed ID: 1682967
[TBL] [Abstract][Full Text] [Related]
12. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function.
Cleghorn JM; Kaplan RD; Szechtman B; Szechtman H; Brown GM; Franco S
J Clin Psychiatry; 1991 Jan; 52(1):26-30. PubMed ID: 1671032
[TBL] [Abstract][Full Text] [Related]
13. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
[TBL] [Abstract][Full Text] [Related]
14. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.
Simhandl C; Meszaros K
J Psychiatry Neurosci; 1992 Mar; 17(1):1-14. PubMed ID: 1349823
[TBL] [Abstract][Full Text] [Related]
15. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates.
Bilder RM; Goldman RS; Robinson D; Reiter G; Bell L; Bates JA; Pappadopulos E; Willson DF; Alvir JM; Woerner MG; Geisler S; Kane JM; Lieberman JA
Am J Psychiatry; 2000 Apr; 157(4):549-59. PubMed ID: 10739413
[TBL] [Abstract][Full Text] [Related]
16. Memory impairment in schizophrenia: its extent, affiliations and neuropsychological character.
Tamlyn D; McKenna PJ; Mortimer AM; Lund CE; Hammond S; Baddeley AD
Psychol Med; 1992 Feb; 22(1):101-15. PubMed ID: 1349439
[TBL] [Abstract][Full Text] [Related]
17. Drug-responsive symptoms during early neuroleptic treatment.
Mazure CM; Nelson JC; Jatlow PI; Bowers MB
Psychiatry Res; 1992 Feb; 41(2):147-54. PubMed ID: 1574541
[TBL] [Abstract][Full Text] [Related]
18. Stability of cognitive functioning early in the course of schizophrenia.
Nopoulos P; Flashman L; Flaum M; Arndt S; Andreasen N
Schizophr Res; 1994 Dec; 14(1):29-37. PubMed ID: 7893619
[TBL] [Abstract][Full Text] [Related]
19. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.
Perlick DA; Rosenheck RA; Kaczynski R; Bingham S; Collins J
Schizophr Res; 2008 Feb; 99(1-3):192-9. PubMed ID: 17851042
[TBL] [Abstract][Full Text] [Related]
20. Clinical predictors of relapse following neuroleptic withdrawal.
Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
